Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3942 | Telmisartan Wiki | 0.58 |
| drug2028 | Itraconazole Wiki | 0.58 |
| drug2374 | Midazolam Wiki | 0.45 |
Navigate: Correlations HPO
There is one clinical trial.
In Part 1, the primary objective is to investigate the effect of multiple doses of itraconazole, an inhibitor of CYP3A4, on the pharmacokinetic (PK) profile of a single dose of ASTX660. In Part 2, the primary objective is to investigate the effect of a single dose of ASTX660 on the pharmacokinetics of the CYP3A4 substrate midazolam and its metabolite, 1-hydroxy midazolam. Safety and tolerability of a single dose of ASTX660 in the absence and presence of multiple doses of the CYP3A4 inhibitor itraconazole and in the presence of a single dose of the CYP3A4 substrate midazolam will also be evaluated.
Description: Maximum plasma concentration
Measure: Pharmacokinetic parameter of ASTX660: Cmax Time: From predose up to Day 14Description: Area under the plasma concentration versus time curve from time zero to the last measurable concentration
Measure: Pharmacokinetic parameter of ASTX660: AUC0-t Time: From predose up to Day 14Description: Area under the plasma concentration versus time curve from time zero to 24 hours
Measure: Pharmacokinetic parameter of ASTX660: AUC0-24 Time: From predose up to Day 14Description: Area under the plasma concentration versus time curve from time zero extrapolated to infinity
Measure: Pharmacokinetic parameter of ASTX660: AUC0-inf Time: From predose up to Day 14Description: Maximum plasma concentration
Measure: Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: Cmax Time: From predose up to Day 9Description: Area under the plasma concentration versus time curve from time zero to the last measurable concentration
Measure: Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-t Time: From predose up to Day 9Description: Area under the plasma concentration versus time curve from time zero to 24 hours
Measure: Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-24 Time: From predose up to Day 9Description: Area under the plasma concentration versus time curve from time zero extrapolated to infinity
Measure: Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-inf Time: From predose up to Day 9Description: Total apparent clearance
Measure: Pharmacokinetic parameter for ASTX660: CL/F Time: From predose up to Day 14Description: Observed terminal half-life
Measure: Pharmacokinetic parameter for ASTX660: t1/2 Time: From predose up to Day 14Description: Total apparent clearance
Measure: Pharmacokinetic parameter for midazolam: CL/F Time: From predose up to Day 9Description: Observed terminal half-life
Measure: Pharmacokinetic parameter for midazolam: t1/2 Time: From predose up to Day 9Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports